

The Trendlines Group

Building value 2015-2019

Steve Rhodes
Chairman and CEO

13 February 2019

Legal disclaimer

Important notice

This presentation is for informational purposes only and does not constitute or form any part of any offer for sale or subscription of, or solicitation of, any offer to buy or subscribe for any securities of The Trendlines Group Ltd. (“Company”) or any of its portfolio companies nor shall it or any part of it form the basis of, or be relied on in connection with, any contract, commitment or any investment decision whatsoever in Singapore, Israel, the United States or in any other jurisdiction. The summary information herein does not purport to be complete. The information in this presentation should not be relied upon as any representation or warranty, express or implied, of the Company. No reliance should be placed on the fairness, accuracy, completeness or correctness of the information or opinions contained in this presentation. The information is subject to change without notice.

The past performance of the Company is not necessarily indicative of its future performance. This presentation may contain statements that constitute forward-looking statements which involve risks and uncertainties. These statements include descriptions regarding the intent, belief or current expectations of the Company or its officers with respect to the results of business operations and financial condition, industry, environment and future events and plans of the Company. Such forward-looking statements are not guarantees of future results, performance or achievements. Actual results, performance or achievements of the Company may differ from those expressed in the forward-looking statements as a result of various factors and assumptions, such as known and unknown risks and uncertainties, including those risk factors discussed in our Offer Document dated 16 November 2015 and in our other filings with the SGXNET. By their nature, forward-looking statements involve risks and uncertainties because they relate to events and depend on circumstances that may or may not occur in the future. In light of these risks and uncertainties, actual events, results and developments could differ materially from those expressed or implied by the forward-looking statements. Reliance should not be placed on these forward-looking statements, which reflect the view of the Company or its officers as of the date of this presentation only. The Company does not undertake any obligation to update or revise any of the forward-looking statements, whether as a result of new information, future events or otherwise.

None of the Company or any of its respective affiliates, advisers or representatives shall have any liability whatsoever for any loss howsoever arising, whether directly or indirectly, from any use, reliance or distribution of this presentation or its contents or otherwise arising in connection with this presentation.

Neither this presentation nor any of its contents may be used without the prior written consent of the Company.

A game changer in heart pump technology




In December 2018,
medical history was made

Bloomberg

Technology
Heart Pump With Wireless Charging Implanted by Kazakh Doctors

By [Nariman Gizitdinov](#)
February 6, 2019, 5:00 AM GMT+2 Updated on February 6, 2019, 11:08 AM GMT+2

► First known human experience with this technology: JRL
► Discharged patient with device seen swimming, working out



X-ray showing the mechanical heart pump. Source: Leviticus Cardio Facebook

Doctors in Kazakhstan said Wednesday they had successfully implanted a mechanical heart pump charged wirelessly by an Israeli device, a development aimed at improving life for very ill patients awaiting transplants.

The operation was performed in December at the National Research Center for Cardiac Surgery in Astana, the Israeli technology company Leviticus Cardio said in an emailed statement.

"The patient has been discharged from the hospital and is back leading a normal life," the company said in the statement. It did not disclose a timeline.

in this article

Share this article

Share
Facebook
Twitter
LinkedIn
Email

The Journal of Heart and Lung Transplantation

The Official Publication of the International Society for Heart and Lung Transplantation

Articles & Issues ▾ Press Releases ▾ For Authors ▾ Journal Info ▾ Subscribe ▾ ISHLT ▾ ISHLT Reg

Contact the Journal

All Content Search Advanced Search

Articles in Press

Article in Press

First Human Use of a Wireless Coplanar Energy Transfer Coupled with a Continuous-flow Left Ventricular Assist Device

[Yuryi Pyta](#), MD, [Jiri Maly](#), MD, PhD, [Mahabbat Bekbosynova](#), MD, [Roman Salov](#), MBA, [Stephan Schueler](#), MD, PhD, FRCS, [Bart Meyns](#), MD, PhD, [Yigal Kassif](#), MD, [Massimo Massetti](#), MD, PhD, [Michael Zilbershlag](#), BSc, [Ivan Netuka](#), MD, PhD

Open Access PlumX Metrics

DOI: <https://doi.org/10.1016/j.healun.2019.01.1316>

Article Info



The operation itself took 4 hours
The new system was implanted with **no complications**



The technology **Leviticus** has developed
will **transform** the heart pump industry **as a whole**

A game changer in heart pump technology

Fully Implanted Ventricular Assist Device (FIVAD) , a fully implanted VAD system, powered wirelessly using both internal and external components allowing patients to walk around without any physical impediments for up to 8 hours a day

Achievements

- First in Human implant of FIVAD with successful 40+ day follow-up
- Awarded US\$950,000 grant from BIRD Foundation together with Jarvik Heart, global #3 in the LVAD market
- Fully operational system
- ISO 13485
- Concept validated by key opinion leaders
- High visibility among LVAD players
- Raised US\$9.2 million to date
- IP: 12 issued patents; several pending in the United States

CEO: Michael Zilbershlag

Trendlines' director: Steve Rhodes



Leviticus provides the day-to-day power needs of LVADs

trendlines
portfolio



bus. dev.
stage

In November 2015...



Companies started

November 2015	February 2019
60	93

Vital BioMed

Phytolon
Natural Food Colorants

AgroScout
Detection Done Right

ALGAHEALTH

BiPS
Medical

ceretrieve

FruitSpec.

LIMACA
MEDICAL IMAGING

IBI-Ag
Innovative Bio Insecticides

interVaal

M
METOMOTION

ZYGOFIX

Portfolio value

November 2015	Q3 2018
US\$80 million	US\$ 102.5 million Up \$22.5 million
	28% increase in value

Exits

November 2015	February 2019
5	8

INSPIRO
Medical

StimatixGI
Medical Solutions

FLOWSENSE

ETVIEW

BIOSIGHT

PolyTouch
Medical

Innolapsurgical

MitrAssist

Start-up to commercialization

	November 2015	February 2019
Stimatix GI	2-3 years from market	In market

StimatixGI
Medical Solutions

B | BRAUN
SHARING EXPERTISE

Strategic investors

November 2015	February 2019	
B.Braun	<p>B.Braun (ApiFix, Fidmi, Gordian, Trendlines Medical Singapore)</p> <p>Bayer (Fund, IBI-Ag)</p> <p>Cogentix (Vensica)</p> <p>Johnson & Johnson (OrthoSpin)</p> <p>Neovia (AquiNovo)</p>	<p>Nutreco (ViAqua)</p> <p>Hubei Forbon Technologies (Saturas)</p> <p>Miguel Torres Winery (Saturas)</p> <p>Yotvata (EdenShield)</p> <p>Agar (MemTech)</p> <p>VisVires New Protein (ViAqua Therapeutics)</p>

Singapore partnerships

November 2015	February 2019	
0	NHG SGH K2 Global A*STAR SEEDS Capital	Enterprise Singapore New Protein Ventures Sirius Capital Asdew Partners



Activity in Singapore

	November 2015	February 2019
Best practices recognition	-	SIAS Good Governance Award Best IR for Catalist Company
Incubator in Singapore	-	Trendlines Medical Singapore
SIIRD projects	-	Trendlines Labs – SGH SolChip – Styl Solutions
Conferences	-	ReThink Agri-Food Innovation; Indoor Ag-Con



Looking ahead: Trendlines AgriFood fund + AFIC

- **US\$40 million** agrifood tech-focused venture fund
 - Over-subscriptions accepted up to US\$ 60 million
- The Fund will employ a blended **early/late-stage investment strategy**
 - 1/3 invested in Singapore-based, early-stage agrifood tech start-ups
 - 2/3 invested in commercialization-stage agrifood tech companies from around the world, particularly Israel
- Trendlines Agrifood Innovation Center (AFIC, will be the fund manager and will provide **incubation** to start-up portfolio companies; **market entry** and **development support** to the later-stage portfolio companies
- **Goals** of blended investment strategy
 - To achieve early exits
 - To attain IRR of at least 20%
- MAS license pending
- Applying for enhanced tier fund tax incentive under 13X or 13R Income Tax Act

Commitment of Singapore Government Support

- Lead investor: **Prominent Singapore investment fund**

Committed to invest 25% of fund, up to US\$10 million

- **Enterprise Singapore**

- Early-stage companies can access proof-of-concept and proof-of-value funding, up to total of SGD 750,000 per company at favorable terms
- Application pending for grant funding for incubator

- Agreement to co-invest with Fund: **SEEDS Capital** (Enterprise Singapore)

- 70% of SEEDS' profits paid to the Fund, increasing Fund yield

Management changes



Todd Dollinger
Chairman & CEO



Barak Singer
CEO Trendlines Incubators
Israel



Nir Goldenberg
CEO Trendlines Labs



Nitza Kardish, Ph.D.
VP The Trendlines Group



Steve Rhodes
Chairman & CEO




Haim Brosh
CFO &
Joint Co. Sec'y.



Eric Loh
CEO Trendlines Medical
Singapore

Factors driving value expansion

- 
- 1 Increasing number of portfolio companies
 - 2 Building portfolio companies' value through intense support
 - 3 Building companies for exit
 - 4 Trendlines Labs: creating new IP and new portfolio companies
 - 5 Planned Agrifood Innovation Center in Singapore - AFIC



Creating and developing companies
to improve the human condition

SGX: 42T
OTCQX: TRNLY

+972.72.260.7000
www.trendlines.com



Steve Rhodes, Chairman & CEO
steve@trendlines.com

13 February 2019